Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epix Pharmaceuticals is seeking a new partner to collaborate on the development of a magnetic resonance imaging agent after Schering AG decided not to exercise an option relating to the research.
Subscribe to our email newsletter
Epix said following Berlin-based Schering’s decision not to exercise its option it will retain full rights to the EP-2104R program. Schering is in the process of being acquired by fellow German drug maker Bayer AG.
US-based Epix, which recently announced a definitive agreement to merge with Predix Pharmaceuticals Holdings, says it intends to actively pursue a new collaboration after the phase IIa feasibility studies of EP-2104R generated encouraging images. Following these results the group anticipates the compound could have a potential role in imaging medicine.
EP-2104R is Epix’s second novel imaging agent in human clinical trials. It is designed to detect blood clots using an MRI machine.